Skip to Content
Merck
CN
  • Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways.

Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways.

Journal of Cancer (2017-01-11)
Sami Benzina, Jason Harquail, Roxann Guerrette, Pierre O'Brien, Stéphanie Jean, Nicolas Crapoulet, Gilles A Robichaud
ABSTRACT

The study of genetic factors regulating breast cancer malignancy is a top priority to mitigate the morbidity and mortality associated with this disease. One of these factors, Pax-5, modulates cancer aggressiveness through the regulation of various components of the epithelial to mesenchymal transitioning (EMT) process. We have previously reported that Pax-5 expression profiles in cancer tissues inversely correlate with those of the Focal Adhesion Kinase (FAK), a potent activator of breast cancer malignancy. In this study, we set out to elucidate the molecular and regulatory relationship between Pax-5 and FAK in breast cancer processes. Interestingly, we found that Pax-5 mediated suppression of breast cancer cell migration is dependent of FAK activity. Our mechanistic examination revealed that Pax-5 inhibits FAK expression and activation. We also demonstrate that Pax-5 is a potent modulator of FAK repressors (p53 and miR-135b) and activator (NFκB) which results in the overall suppression of FAK-mediated signaling cascades. Altogether, our findings bring more insight to the molecular triggers regulating phenotypic transitioning process and signaling cascades leading to breast cancer progression.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-FAK Antibody, clone 4.47, clone 4.47, Upstate®, from mouse
Sigma-Aldrich
Anti-phospho-Src (Tyr418) Antibody, Upstate®, from rabbit